65,437 trials
Rheumatoid Arthritis
Primary: Percentage of Patients With an Improvement of at Least 50% in American College of Rheumatology (ACR) Score (ACR50) From Baseline at Week 24 — 30.1; 11.2 Percentage of…
Febrile Neutropenia
Primary: Composite Primary Endpoint: Number of Participants With an Overall Favorable Response to Echinocandin Therapy for Empiric Antifungal Therapy for Persistent Febrile…
Alcoholism
Primary: The Primary Outcome Measure Will be Subjects Ethanol Consumption Over the Course of the Drug Treatment Period as Assessed by the Timeline Followback Method — -4.9…
Diabetes · Diabetes Mellitus, Type 2
Primary: Mean Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c) at Week 26 — -1.24; -1.5; -0.9 Percentage point of total HbA1c — p=0.0001
Meningococcal Meningitis · Meningococcal Infections
Primary: Number of Subjects With at Least One Severe Systemic Reaction, Ages 19 to 55 Years — 95; 46 Subjects
Skin Infections, Bacterial
Primary: Number of Participants With Clinical Success and Failure at Follow-up (7-9 Days Post Therapy) for the Primary Efficacy Population — 184; 75; 62; 38 participants — p=0.098
Papillomavirus Infections · Genital Diseases, Female
Primary: Number of Subjects With Injection Site Adverse Experiences — 247; 248; 266; 107 Participants
Postmenopausal Osteoporosis
Primary: Percent Change From Baseline in Total Hip Bone Mineral Density — 1.05; 1.9 Percent Change — p=<0.0001
Type 2 Diabetes Mellitus
Primary: Insulin Secretion Rate (ISR) During 190 - 340 Minutes Post-dose — 9.73; 8.03 ng/min — p=<0.001
Asthma
Primary: Number of Patients With Clinical Adverse Experiences (CAE) Reported by Patients - Base Study — 202; 406; 26; 55 Participants
Alzheimer Disease
Primary: Number of Participants for Change From Baseline for Clinical Global Impressions of Improvement (CGI-I) at Week 12 — 26; 5; 27; 103 participants — p=0.0023
Arthritis
Primary: Change in Balance — 0.2; 1.2; 1.0 units on a scale
Lymphoma, Non-Hodgkin
Primary: Event-free Survival (EFS) — 9; NA Months
Heart Failure
Primary: Number of Participants That Experienced One Component of the Composite Clinical Endpoint of All Cause Death or Hospitalization for Heart Failure — 889; 828 Participants…
Carcinoma, Renal Cell
Primary: Progression-free Survival — 9.2; 4.2 months — p=.0000001